---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-011852"
form_type: "8-K"
ticker: null
cik: "0001783032"
company_name: "Elevation Oncology, Inc."
filed_at: "2023-07-13T23:59:59+00:00"
generated_at: "2026-06-13T08:50:29.605632+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Elevation Oncology appoints Joseph Ferra as permanent CEO and Tammy Furlong as CFO

## Summary
- Joseph J. Ferra Jr. appointed President & CEO effective July 12, 2023; he steps down as CFO.
- Tammy Furlong, previously VP of Finance, appointed CFO effective July 12, 2023.
- Ferra's base salary increased to $600,000, target bonus 50%, and options for 35,000 shares.
- Furlong's base salary increased to $430,000, target bonus 40%, and options for 53,433 shares.

## SEC filing metadata
- accession: 0001558370-23-011852
- form_type: 8-K
- cik: 0001783032
- company_name: Elevation Oncology, Inc.
- filed_at: 2023-07-13T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783032/000155837023011852/0001558370-23-011852-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783032/000155837023011852/elev-20230712x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-011852
- JSON: https://secwatch.observer/filing/0001558370-23-011852.json
- Plain text: https://secwatch.observer/filing/0001558370-23-011852.txt

## Key facts
- Executive change
  Joseph J. Ferra, Jr. was appointed as President and Chief Executive Officer at Elevation Oncology, Inc..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: appointed Joseph J. Ferra, Jr. as (i) President and Chief Executive Officer of the Company and (ii) a member of the Board, to serve as a Class I director with an initial term expiring at the Company’s 2025 Annual Meeting of Stockholders, in each case, effective as of July 12, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783032/000155837023011852/0001558370-23-011852-index.htm
- Executive change
  Joseph J. Ferra, Jr. was appointed as member of the Board at Elevation Oncology, Inc..
  - Action: appointed
  - Role: member of the Board
  source text: appointed Joseph J. Ferra, Jr. as (i) President and Chief Executive Officer of the Company and (ii) a member of the Board, to serve as a Class I director with an initial term expiring at the Company’s 2025 Annual Meeting of Stockholders, in each case, effective as of July 12, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783032/000155837023011852/0001558370-23-011852-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.